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We describe the development of nanoscale polymer drug carriers for the combinational delivery of an anticancer
drug (doxorubicin: DOX) along with super paramagnetic iron oxide nanoparticles (IONPs). The drug molecules
were electrostatically loaded into both block copolymer self-assembled nanoassemblies (SNAs) and cross-linked
nanoassemblies (CNAs). Both nanoassemblies entrapped DOX and IONPs either individually or in tandem,
maintaining sub-100 nm diameter. The IONP-loaded nanoassemblies generated heat in the presence of an
alternating magnetic field (AMF). Incorporation of the drug payload, DOX, showed no adverse effects on the
heating profile. Drug release from the SNAs and CNAs was accelerated as temperature increased from the
normal body temperature (37°C) to a mild hyperthermic condition (40  42°C). CNAs released DOX faster than
SNAs regardless of an incubation temperature. CNAs co-entrapped IONPs and DOX were more stable than
SNAs in aqueous solutions for five days. These results suggest that block cop olymer cross-linked nanoassemblies
provide viable delivery platforms for combination delivery of inorganic molecules, anticancer drugs, and
potentially other various biologically active substances.
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INTRODUCTION
Polymer nanoassemblies, molecular complexes typically
prepared from biocompatible block copolymers, are widely used in
current cancer research as drug carriers that can circulate in the
body for a prolonged period of time and accumulate in tumor
tissues efficiently (Ishida et al., 1999; Lee et al., 2010). Previous
studies have demonstrated that spherical polymer nanoassemblies,
20 ~ 200 nm vesicles and particles, can entrap various molecules
for diagnosis, imaging, and treatment of cancer (Bae et al., 2009;
Khemtong et al., 2009; Torchilin 2011). In comparison to
conventional anticancer therapy with small molecules (< 1,000
Da), chemotherapy using polymer nanoassemblies as drug carriers
can reduce non-specific drug distribution in normal tissues by
increasing the concentration of drug payloads preferentially in
tumors (Matsumura et al., 1986; Maeda et al., 2000). Polymer
nanoassemblies are also shown to overcome other pharmaceutical
obstacles for anticancer drugs, such as poor water solubility, low
bioavailability, and unacceptable systemic toxicity (Bae et al.,
2009).
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Despite these potential benefits, polymer nanoassemblies
still need to be improved to control drug release in tumors for
effective cancer chemotherapy because most anticancer drugs are
designed to kill fast growing cancer cells by inhibiting signal
pathways for cell survival during the cell division, and drug
concentrations and timing of treatment are crucially important to
maximize therapeutic efficacy (Kim et al., 2002; Los et al., 2003;
Fulda et al., 2006). Although polymer nanoassemblies that release
drug slowly in the blood are expected to reduce systemic toxicity,
they could also release drug too slowly to maintain therapeutic drug
concentrations in tumor tissues (Fang et al., 2011). These facts
suggest that polymer nanoassemblies that accelerate drug release
selectively in tumor tissues in a controlled manner may improve
anticancer chemotherapy while reducing systemic toxicity.
Numerous approaches have been developed to control
drug release from polymer nanoassemblies in response to external
stimuli, such as pH, light, ultrasound, and heat alone or in
combination (Sanvicens et al., 2008; Bae et al., 2009). Heat is
particularly useful to control drug release because the body
temperature is precisely regulated. Various methods are currently
available to increase temperature in specific tissues locally, using
.
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heating probes, plates, and inorganic nanomaterials (e.g. gold and
iron oxide). Among these heating sources, iron oxide nanoparticles
(IONPs) with superparamagnetic properties have drawn
considerable attention because they can generate heat in the
presence of an alternating magnetic field (AMF) (Neuberger et
al., 2005; Frimpong et al., 2008; Frimpong et al., 2010; Frimpong
et al., 2010; Meenach et al., 2010; Meenach et al., 2010; Satarkar
et al., 2010; He et al., 2011; Satarkar et al., 2011). IONPs can be
also used as a T2 contrast agent for magnetic resonance
imaging (Bulte et al., 2004). Such dual heating and imaging
properties enable IONPs to be used for theranostics (Sumer et al.,
2008). However, IONPs have poor particle stability and
agglomerate easily in aqueous solutions, causing toxicity to the
human body (Mahmoudi et al., 2009; Singh et al., 2010; Soenen
et al., 2010; Mahmoudi et al., 2011; Shen et al., 2012). Particle
stability of IONPs can be improved by surface modification or
using solubilizer (e.g. surfactants and water soluble
polymers) (Laurent et al., 2008). Hydrophobic and ionic
interactions have been identified as two major factors for block
copolymers to self-assemble into polymer nanoassemblies, and
regardless of the payload, particle size and stability are critically
important for the polymer nanoassemblies to achieve successful
tumor accumulation (Jain et al., 2008; Lin et al., 2008), yet

critical issues, such as precipitation, agglomeration, and protein
adsorption in vivo, are not resolved completely.
For these reasons, previous studies have been focused
mainly on stabilizing IONP-loaded nanoparticles, and little efforts
have been made to co-entrap IONPs and other therapeutic agents
into a single nanoparticle for combination delivery (Harris et al.,
2003; Prompruk et al., 2005; Kumagai et al., 2007; Papaphilippou
et al., 2009; Konwarh et al., 2010; Lee et al., 2011; Schladt et al.,
2011; Xie et al., 2011; Min et al., 2012). In this study, we focus on
the development of novel nanoparticle formulations for coentrapment and co-delivery of IONPs and anticancer agents. We
hypothesize that (1) stable and safe IONP-loaded nanoparticles can
be prepared by precipitating IONPs inside polymer
nanoassemblies, and (2) these nanoassemblies can be used to coentrap therapeutic agents without compromising AMF-responsive
heating profiles of the IONPs. To test these hypotheses, we have
prepared and characterized the self-assembled nanoassemblies
(SNAs) (Eckman et al., 2012) and cross-linked nanoassemblies
(CNAs) (Lee et al., 2011; Ponta et al., 2011; Scott et al., 2011)
from biocompatible poly(ethylene glycol)-poly(aspartate) block
copolymers, entrapping IONPs and an anticancer drug
(doxorubicin: DOX), and thus potentially accelerating drug release
in tumors in response to AMF (Figure 1).

.

Fig 1. Polymer nanoassemblies used in this study to entrap IONPs and DOX in combination. Self-assembled nanoassemblies (SNAs, light blue) and cross-linked
nanoassemblies (CNAs, dark green) were prepared from the same block copolymer
[PEG-poly(aspartate)],
and categorized into eight groups (1: IONP-loaded
MATERIAL
AND METHODS
SNAs; 2: DOX-loaded SNAs; 3: Physical mixture of 1 and 2; 4: IONP/DOX co-entrapped SNAs; 5: IONP-loaded CNAs; 6: DOX-loaded CNAs; 7: Physical
mixture of 5 and 6; and 8: IONP/DOX co-entrapped CNAs).
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MATERIALS
Triphosgene, L-aspartic acid β-benzyl ester (BLA),
N,N’-diisopropylcarbodiimide (DIC), N-hydroxysuccinimide
(NHS),
4-(dimethylamino)pyridine
(DMAP),
anhydrous
tetrahydrofuran (THF), anhydrous hexane, diethyl ether,
dimethylsulfoxide (DMSO), phosphate buffer solution, phosphate
buffered saline (PBS), 1,8-diaminooctane, doxorubicin
hydrochloride (DOX-HCl), sodium hydroxide (NaOH), iron(II)
chloride tetrahydrate, iron(III) chloride hexahydrate, and
ammonium hydroxide (NH4OH) were purchased from SigmaAldrich (USA). α-Methoxy-ω-amino poly(ethylene glycol) (PEG,
12 kDa) was purchased from NOF Corporation (Japan). Dialysis
bags with molecular weight cut off (MWCO) 6  8 kDa and SlideA-Lyzer G2 dialysis cassettes with MWCO 10 kDa, were
purchased from Fisher Scientific (USA). SpectraPor 6 dialysis
tubing with MWCO 50 kDa was purchased from Spectrum Labs
(USA).
Block copolymer synthesis
Block copolymers were synthesized as reported
previously (Bae et al., 2005; Lee et al., 2011). β-Benzyl-Laspartate N-carboxy anhydride (BLA-NCA) was prepared as a
monomer by reacting BLA with triphosgene (1.3 molar
equivalent) in dry THF (50  100 mg/mL) at 45 C until the
solution turned clear. Anhydrous hexane was added to the solution
to recrystallize BLA-NCA at -20 C. The amino group of PEG was
used to initiate polymerization of BLA-NCA in DMSO (50
mg/mL) at 45 C under nitrogen for 2 days. The polymerization
produced PEG-poly(β-benzyl L-aspartate) [PEG-PBLA], followed
by precipitation in diethyl ether and freeze drying. The block
copolymer composition was determined by proton nuclear
magnetic resonance (1H-NMR) spectra from PEG (3.5 ppm) and
benzyl groups (7.3 ppm). The purity of block copolymers was
determined by gel permeation chromatography (GPC, Shimadzu
LC20), using PBS mobile phase and PEG standard.
Synthesis of CNAs
The CNAs were synthesized as previous reported with
slight modification (Lee et al., 2011). A two molar excess of
NaOH was added to PEG-PBLA to remove the benzyl groups.
Excess NaOH and other impurities were removed by dialysis. The
solution was treated further with HCl to remove sodium salt, and
freeze dried to collect PEG-poly(aspartate) [PEG-p(Asp)]. PEGp(Asp) was dissolved in DMSO to a final concentration of 50
mg/mL. DIC, NHS, and DMAP were added to the solution at a
molar ratio of 4:4:0.2 with respect to the number of the aspartate
units of PEG-p(Asp). This solution was mixed with 1,8diaminooctane [0.5 equivalent to carboxyl groups of p(Asp)] at 45
C for 72 hours. CNAs were dialyzed against water, and collected
by freeze drying.
Preparation and Characterization of Nanoassemblies
Entrapping IONPs and DOX
Iron oxide (Fe3O4) was formed in the presence of either
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PEG-p(Asp) block copolymers or CNAs to simultaneously
precipitate and entrap IONPs inside polymer nanoassemblies. Iron
ions were added to PEG-p(Asp) and CNAs in a molar ratio of 1:1
(a ratio of 2:1 of Fe3+:Fe2+) with respect to carboxylic groups on
the polymer chains. Ammonium hydroxide was then slowly added
to the solution to precipitate the iron oxide, producing SNAs and
CNAs entrapping IONPs (1 and 5 in Figure 1). IONPs that were
formed outside of the polymer nanoassemblies aggregated and
precipitated in the solutions while the IONPs entrapped inside the
SNAs and CNAs remained soluble in the supernatant. Free IONPs
as well as free ions (iron and sodium) were removed from the
solution by centrifugation and dialysis. SNAs and CNAs
entrapping IONPs were collected by freeze drying. DOX was
entrapped in the polymer nanoassemblies through combined ionic
and hydrophobic interactions. DOX-HCl was mixed with PEGp(Asp) or CNAs in deionized water, followed by dialysis and
ultracentrifugal filtration (30 kDa) until no free DOX was
detected. SNAs and CNAs entrapping DOX were collected by
freeze drying (2 and 6 in Figure 1). Polymer nanoassemblies coentrapping IONPs and DOX were prepared by mixing DOX-HCl
with the polymer nanoassemblies pre-loaded with IONPs. The
products were collected by dialysis against water and freeze drying
(4 and 8 in Figure 1). Physical mixtures of individual
nanoassemblies entrapping either IONPs or DOX separately were
prepared as comparison (3 and 7 in Figure 1). IONP loading yields
were determined by weight % (wt%), using thermogravimetric
analysis (TGA) instruments. Fourier transform infrared
spectroscopy (FT-IR) was used to confirm the presence of
polymers in IONP-loaded nanoassemblies. DOX entrapment
yields were quantified by UV-Vis absorbance measurements at
480 nm. Particle sizes of all samples were determined by dynamic
light scattering (DLS) measurements (Zetasizer Nano ZS,
Malvern). Data are shown as average from triplicate measurements
± standard deviation (SD).
Heating of IONP-Loaded Polymer Nanoassemblies
Heating capability of IONP-loaded SNAs and CNAs was
determined in the presence of AMF, using a custom made
induction power supply (Taylor Winfield, MMF-3-135/400-2).
IONP-loaded nanoassemblies were dissolved in deionized water at
2 mg/mL and placed in a 1.5 mL microtube. The solution was
placed inside the coil of the AMF unit, using a Luxtron FOT lab
kit temperature probe (LumaSense Technologies) to monitor the
overall solution temperature of the sample. A baseline temperature
was obtained from a blank solution for 30 seconds and the AMF
was switched on at 70% power, corresponding to a field strength
of approximately 59.3 kA/m at 300 kHz. The temperature was then
monitored for 15 minutes. Images of the AMF-induced heating of
the IONP-loaded nanoassemblies were captured using an infrared
(IR) camera (SC4000, FL-IR Systems).
IONP-loaded nanoassemblies in water (2 mg/mL) were
placed in a 35 mm culture dish and set on top of the AMF coil
(33.4 kA/m at 300 kHz) for taking IR images. The change in the
heating profile based on IONP concentration was evaluated
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through the application of AMF to varying IONP-CNA
concentrations. The total IONP-CNA concentrations were set at 1,
2.5, and 5 mg/mL based on IONPs, followed by the application of
AMF. The initial temperature was held at either 25ºC or 37ºC by a
customized warming chamber.
Evaluation of Temperature Dependent Drug Release
The influence of heat on drug release from polymer
nanoassemblies was determined by evaluating SNAs and CNAs
that co-entrapping IONPs and DOX. The polymer nanoassemblies
(300 µL of 2 mg DOX/mL) were put in three dialysis cassettes
(Slide-A-Lyzer G2, MWCO 10 kDa, Thermo Scientific, USA).
The sample solutions were dialyzed in excess phosphate buffer
solutions (pH 7.4, 20 mM) while the temperature was maintained
at either 37ºC or 45ºC. An aliquot of 20 µL was taken out of each
dialysis cassette at 0, 0.5, 1, 2, 4, and 6 hours. DOX remaining in
the dialysis cassettes were quantified by UV/Vis absorbance at 480
nm. All experiments were performed in triplicate.
Stability of Nanoassemblies
The stability of SNAs and CNAs co-entrapping IONPs
and DOX was investigated over a period of 5 days. The polymer
nanoassemblies were dissolved in deionized water at 2 mg/mL,
and added to a disposable capillary tube. The nanoparticles were
stored at room temperature and the particle size was observed by
DLS in triplicate on days 1, 3, and 5.
RESULTS AND DISCUSSION
Synthesis of block copolymers and CNAs
1
H-NMR analysis determined that polymerization of
BLA-NCA produced PEG-PBLA with 28 aspartate repeating
units. GPC was used to confirm the purity of the polymer and the
cross-linking of PEG-p(Asp) with 1,8-diaminooctane. A single
peak of PEG-p(Asp) on GPC shifted to a higher molecular range
with a shorter elution time after the cross-linking reaction (Figure
2).

molecular weight of CNAs was approximately 129 kDa, indicating
that one CNA particle contained 7 ~ 8 block copolymer chains.
These results were consistent with what we observed
previously (Lee et al., 2011; Eckman et al., 2012).
Entrapment of IONPs and DOX
IONPs are normally stabilized with citric acid or
surfactants to avoid agglomeration (Laurent et al., 2008). In this
study, we used PEG-p(Asp) or CNAs as stabilizers to
simultaneously prepare and entrap IONPs inside polymer
nanoassemblies. This approach allowed us to control the particle
size of polymer nanoassemblies within a clinically relevant range
(< 100 nm). Successful incorporation of IONPs into the polymer
nanoassemblies was achieved at a 2:1 ratio of Fe3+:Fe2+ in solution
with an equivalent amount of carboxyl groups of PEG-p(Asp) or
CNAs. The solution containing iron ions and polymers formed
dark brown precipitates immediately after NH4OH was added.
IONPs entrapped in polymer nanoassemblies were readily
separated from free IONPs by centrifugation as the entrapped
IONPs remained soluble in aqueous solutions. The supernatant
was collected and dialyzed to remove unreacted iron ions and
other impurities, followed by freeze drying.
DOX was also successfully entrapped in either empty or IONPloaded nanoassemblies. DOX and PEG-p(Asp) block copolymers
formed SNAs spontaneously as they were mixed in deionized
water. The amount of DOX loaded into nanoassemblies was
quantified by UV-Vis absorbance at 480 nm (25.6 wt%). FT-IR
was used to confirm IONP incorporation into polymer
nanoassemblies (Figure 3).

Fig 3. FT-IR characterization (a: IONPs; b: IONP-loaded polymer
nanoassemblies; c: IONP/DOX co-entrapped polymer nanoassemblies; e: ether
peak at 1,100 cm-1; and f: amide peak at 1,650 cm-1).

Fig 2. GPC spectra of PEG (12 kDa), PEG-p(Asp) block copolymers, and
CNAs.

A relatively narrow distribution of the CNAs was also
observed with a Mw/Mn of 1.14. Neither unreacted polymers nor
impurities were detected after purification of CNAs. The average

IONPs are dark brown materials, which were easily detected by
color in our IONP-loaded polymer nanoassemblies after
purification. The ether peak at 1,100 cm-1 and amide at 1,650 cm-1
indicated the presence of PEG and p(Asp), respectively. These
unique polymer peaks appeared in both IONP-loaded
nanoassemblies and nanoassemblies co-entrapping IONP and

Scott et al. / Journal of Applied Pharmaceutical Science 3 (06); 2013: 021-028

DOX while the IONPs alone lacked the peaks of interest. It is
possible that unencapsulated IONPs and free block copolymers
could result in a similar FTIR trace. However, unencapsulated
IONPs precipitate easily and cannot be present in aqueous
solutions, following several purification steps used for IONPloaded
nanoparticles.
TGA
confirmed
that
polymer
nanoassemblies contained 26 wt% of IONPs (Figure 4). The
particle sizes of nanoassemblies are summarized in Table 1,
indicating that the average diameter was less than 100 nanometers
regardless of the nanoassembly composition.
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presence (b) of drug payloads (DOX). IR images show that the
heating efficiency of IONPs inside polymer nanoassemblies
changed substantially inside and over the AMF coil (c and d in
Figure 5B).

Fig 4. TGA characterization and the IONP loading yield in CNAs.
Table 1.Size comparison of polymer nanoassemblies entrapping IONPs and
DOX.

IONP-loaded SNAs
DOX-loaded SNAs
IONP/DOX co-entrapped SNAs
Physical mixture of IONP- and DOX-loaded SNAs
IONP-loaded CNAs
DOX-loaded CNAs
IONP/DOX co-entrapped CNAs

Diameter  SD
(nm)
34.4 ± 6.0
57.7 ± 3.3
54.3 ± 6.5
46.0 ± 8.8
64.0 ± 10.4
70.6 ± 4.7
75.0 ± 11.0

Physical mixture of IONP- and DOX-loaded CNAs

67.5 ± 10.9

Samples

Heating profile of IONP-loaded polymer nanoassemblies
The heating ability of IONPs inside polymer
nanoassemblies was investigated using a temperature probe and an
IR camera in the presence of AMF. In Figure 5A, nanoparticle
solutions (1 ~ 5 mg IONP/mL) reached the hyperthermic
temperature range (40 ~ 42ºC) in 600 seconds in the presence of
AMF. As the concentration of IONP-loaded CNAs increased, the
observed solution temperature also increased. However, the
temperature of solution at 1 mg IONP/mL was always lower than
nanoassembly solutions at higher IONP concentrations (2.5 or 5
mg/mL) and showed no further increase over time. It is noticeable
that initial solution temperatures (37ºC vs 25ºC) did not change the
heating rate of polymer nanoassemblies (Figure 5A and 5B). These
results indicate that the concentration of IONPs in the solution is
the major factor that affects heating profiles of IONP-loaded
polymer nanoassemblies. Figure 5 B indicates that polymer
nanoassemblies retain the heating profile in the absence (a) and

Fig 5. Heating profiles of IONP-loaded CNAs. (A) The changes in solution
temperature upon the application of AMF were observed at different particle
concentrations (control: deionized water). (B) Effects of drug payloads on the
heating profile were also investigated (a: IONP-loaded CNAs alone; b:
IONP/DOX co-entrapped CNAs; c: infrared thermal image of a blank; and d:
thermal images of IONP-loaded CNAs. AMF generating coils are shown in
white circles.)

These results demonstrate the ability to tune the heat
produced by the IONP-loaded nanoassemblies and allow
adjustments in order to minimize heat damage to other normal
tissue outside of the accumulated area while maximizing the
effectiveness of the treatment. In addition, these remotely heatable
nanoassemblies can carry drug payloads at the same time without
compromising the heating profiles, allowing unique hyperthermia
and chemotherapy combination. We envision that, by selectively
applying an AMF to the area of interest after the nanoparticles
have accumulated in the tumor, heat and the accelerated drug
release can be confined to the tumor and aid in reducing nonspecific side effects. Remote heating of IONP-loaded polymer
nanoassemblies is useful not only for drug release acceleration but
also for heat-induced therapies such as hyperthermia or
thermoablation (Meenach et al., 2010). The range of temperature
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that these polymer nanoassemblies can modulate is still dependent
largely on the concentration of the nanoassemblies and power of
AMF. We observed a significant decrease in heating efficiency
between polymer nanoassemblies in and over the AMF coil. The
optimal design of AMF-generating devices might improve the
heating of polymer nanoassemblies in vivo, allowing focused
heating for drug release acceleration and therapy. Recent work has
demonstrated IONPs possess a therapeutic effect outside of the
heating of the cancer cells. Magnetic nanoparticles were shown to
reduce cell viability to 2  5% when exposed to an alternating
magnetic
field
even
without
raising
the
solution
temperature (Wust et al., 2002; Marcos-Campos et al., 2011).
Therefore, IONP/DOX loaded polymer nanoassemblies may
exhibit a beneficial therapeutic effect as AMF-responsive
nanomaterials in vivo, although potential effects of AMF and
magnetic fields in vivo (e.g. heating of tissue for 10 minutes as
tested in this study) are not fully understood yet (Lednev 1991;
Walleczek 1992; Grissom 1995).
Temperature-dependent drug release
Drug release patterns from polymer nanoassemblies coentrapping IONPs and DOX were determined at 37ºC and 45ºC
(pH 7.4, 20 mM PBS), corresponding to the physiological and
hyperthermic condition, respectively. Both SNAs and CNAs
accelerated drug release as the temperature increased from 37ºC to
45ºC, although the difference was subtle (Figure 6).

that polymer nanoassemblies entrapping IONPs may have a
similar core environment, where IONPs occupy the center of core
and DOX gets weakly bound to the core. It is also possible that
drug molecules were indeed entrapped inside the nanoassembly
core, yet failed to come out as more than 20% of drugs still
remained in the nanoassemblies. Therefore, accelerated drug
release is likely attributed to temperature-dependent changes in
hydration of PEG of the particles, affecting mainly the drugs along
the boundary region between the core and shell. Hydration is one
of the factors that influence molecular diffusion in a layer and
matrix made of PEG. PEG is a flexible polymer chain, but SNAs
and CNAs tether PEG chains to an IONP-loaded core, providing a
nanoscale PEG compartment in the shell, a physical barrier that
drug molecules need to go through. Therefore, IONPs generating
heat in the presence of AMF may enhance molecular diffusion of
DOX from the polymer nanoassemblies, although we were unable
to direct observe such a phenomenon due to the technical issue to
apply AMF to nanoparticles inside dialysis cassettes in a large
water bath (> 5 L).
Stability of Polymer Nanoassemblies
The stability of polymer nanoassemblies co-entrapping
IONPs and DOX (co-entrapped type) was evaluated in deionized
water over five days, while preparing a mixed solution of
nanoassemblies entrapping IONPs or DOX separately (physically
mixed type) as a control. In Figure 7A, the particle size of
physically mixed SNAs decreased time-dependently, and the
observed particle size decreased by 63% over a period of 5 days (a,
b, and c). Co-entrapped type SNAs retained their particle size for 5
days (d, e, and f in Figure 7A). However, both physically mixed
and co-entrapped SNAs generated precipitates in solutions. The
particle sizes of CNAs remained unchanged in physically mixed
and co-entrapped types (Figure 7B).

Fig 6. The influence of temperature on drug release patterns from SNAs (A)
and CNAs (B). All data points are the average of three measurements ±
standard deviation.

Such accelerated drug release gradually slowed down
after 2 hours, following pseudo-zero order drug release in the early
stage. These bi-modal drug release patterns are expected to finetune optimal drug concentrations in tumors in future in vivo
applications. Although an increased temperature (e.g. 45ºC as
tested in this study) could damage normal tissues, pinpoint
hyperthermia using our IONP-loaded CNAs would reduce such
potential risks. In addition, AMF can switch on and off the heating
and accelerating drug release in a remotely controlled manner,
which will further reduce potential toxicity by hyperthermia with
IONP-loaded nanoassemblies.
Interestingly, there was no significant difference between
SNAs and CNAs in the drug release profile. These results imply

Fig 7. Time-dependent changes in particle sizes of SNAs (A) and CNAs (B)
entrapping IONPs and DOX (a: Physically mixed type on day 1; b: Physically
mixed type on day 3; c: Physically mixed type on day 5; d: Co-entrapped type
on day 1; e: Co-entrapped type on day 3; and f: Co-entrapped type on day 5).
All points are shown the average of three measurements ± standard deviation.
(*: P < 0.05).

No precipitates were observed in CNAs, suggesting that
IONPs and DOX were entrapped effectively in polymer
nanoassemblies due to the cross-linked core. Interestingly the
polymer nanoassemblies co-entrapping IONPs and DOX (both
SNAs and CNAs) showed improved stability with no significant

Scott et al. / Journal of Applied Pharmaceutical Science 3 (06); 2013: 021-028

change in the observed size. One possible reason is that IONPs
could act as a cross-linker and hold multiple block copolymers
together to prevent dissociation. In a physically mixed
formulation, CNAs showed greater particle stability than SNAs.
CNAs with enhanced particle stability can be also used to
introduce other functional groups without compromising the
particle stability. In fact, particle stability is an emerging issue for
nanoparticulate drug carriers as numerous approaches have been
used to control drug release by introducing functional groups that
are sensitive to heat, light, and pH (Bae et al., 2009). Previous
studies employed a method through which pre-formed iron oxide
particles were entrapped in the polymer matrice, particles, or
complexes (Kumagai et al., 2007; Sanvicens et al., 2008; Obena
et al., 2011). On the contrary, we prepared cross-linked
nanoassemblies first, reacted the nanoassemblies with iron ions,
and prepared IONP-loaded nanoassemblies in a single pot. This
method, co-precipitating Fe3O4 iron oxides inside the
nanoassemblies directly, was confirmed efficient and convenient
to prepare IONP-loaded nanoparticles with homogeneous particle
sizes and enhanced particle stability.
CONCLUSION
Block copolymer self-assembled and cross-linked
nanoassemblies (SNAs and CNAs) were prepared in this study to
develop novel nanoscale carriers for the delivery of iron oxide
nanoparticles (IONPs) and anticancer drug (DOX) in combination
to disease sites in the body (e.g. tumors). Polymer nanoassemblies
entrapping IONPs and DOX were successfully prepared by
precipitating iron oxide inside the polymer nanoassemblies, and
the particle sizes were < 100 nm, which is clinically relevant for
macromolecules to accumulate in tumor tissues. IONP-loaded
SNAs and CNAs generated heat in the presence of an alternating
magnetic field (AMF), and the concentrations of IONPs in a
solution played a major role in controlling the temperature.
Heating properties of IONP-loaded nanoparticles were retained
even after entrapping DOX in the SNAs and CNAs. Drug release
from the polymer nanoassemblies was accelerated as temperature
increased, yet the change was subtle presumably because IONPs
occupy the core of nanoassemblies while drug molecules were
weakly bound to the core or entrapped in the shell. Despite similar
drug release patterns, CNAs showed greater particle stability than
SNAs during storage in solutions, suggesting that CNAs would be
a suitable candidate to further develop IONP/DOX co-entrapped
polymer nanoassemblies for future applications, such as AMFmediated remote heating and triggered drug release in vivo.
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